Rule 10b5-1 Arrangement Modified The number of modified. Non-Rule 10b5-1 Arrangement Modified The number of modified. Total current assets Total assets Total current liabilities Total liabilities Class of Stock [Axis] Total stockholders’ equity Balance Balance Total liabilities and stockholders’ equity Total operating expenses Loss from operations Total other income, net Net loss Net loss Net loss (in Dollars) Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net cash used in operating activities Negative operating cash flow (in Dollars) Net cash (used in)/provided by investing activities Net cash provided by financing activities Net increase/(decrease) in cash and cash equivalents Cash and cash equivalents at beginning of the period Cash and cash equivalents at end of the period Business [Abstract] Going Concern [Abstract] Summary of Significant Accounting Policies [Abstract] Antidilutive Securities [Axis] Total anti-dilutive securities Prepaid Expenses [Abstract] Schedule of Prepaid Expenses [Abstract] Total Accrued Expenses [Abstract] Schedule of Accrued Expenses [Abstract] Total Accrued expenses Stock Appreciation Rights [Abstract] Number of Option, Outstanding Balance Number of Option, Outstanding Balance Weighted Average Exercise Price, Outstanding Balance Weighted Average Exercise Price, Outstanding Balance Exercise price (in Dollars per share) Aggregate Intrinsic Value, Outstanding Balance Aggregate Intrinsic Value, Outstanding Balance Stockholders’ Equity [Abstract] Schedule of Changes in Options [Abstract] Statistical Measurement [Axis] Schedule of Changes in Outstanding Warrants [Abstract] Number of Shares, Outstanding Warrants Number of Shares, Outstanding Warrants Weighted Average Exercise Price Per Share, Outstanding Warrants Weighted Average Exercise Price Per Share, Outstanding Warrants Statement of Income Locations Balance [Axis] Commitments and Contingencies [Abstract] Other Postretirement Benefit Plan [Abstract] Segment Reporting [Abstract] Total Research and Development Expense Research and development Subsegments [Axis] Subsequent Events [Abstract] Assets Current assets: Cash and cash equivalents Short-term investments Prepaid expenses Other assets Liabilities and Stockholders’ Equity Current liabilities: Accounts payable Stock appreciation rights Stock appreciation rights liability Research and development expenses (in Dollars) Commitments and Contingencies (See Note 8) Stockholders’ Equity: Preferred stock value Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized (in Shares) Preferred stock, shares issued (in Shares) Preferred stock, shares outstanding (in Shares) Common stock, $0.001 par value, 150,000,000 shares authorized, 104,890,223 and 73,333,622 shares issued and outstanding, respectively Common stock, par value (in Dollars per share) Common stock, par value Common stock, price per share (in Dollars per share) Common stock, shares authorized (in Shares) Common stock, shares issued (in Shares) Common stock, shares outstanding (in Shares) Additional paid-in capital Accumulated deficit Operating expenses: General and administrative Other income: Interest/investment income, net Realized (loss)/gain on short-term investments Unrealized (loss)/gain on short-term investments Loss per common share – basic (in Dollars per share) Loss per common share – diluted (in Dollars per share) Weighted average number of common shares outstanding – basic (in Shares) Weighted average number of common shares outstanding – diluted (in Shares) Stock based compensation Proceeds from issuance of common stock, net Proceeds from issuance of common stock, net (in Shares) Shares issued (in Shares) Shares issued ATM Fees Cashless exercise of pre-funded warrants for common stock Cashless exercise of pre-funded warrants for common stock (in Shares) Issuance of restricted common stock Issuance of restricted common stock (in Shares) Restricted common stock Cash flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation Stock appreciation rights compensation Issuance of restricted common stock Change in operating assets and liabilities: Accounts payable Accrued expenses Cash flows from investing activities Sale of short-term investments Cash flows from financing activities Proceeds from issuance of common stock Non-cash investing and financing activities: Cashless exercise of warrants for common stock Fees for issuance of common stock included in accounts payable Fees for issuance of common stock included in accrued expenses Realized loss/(gain) on short-term investments Unrealized loss/(gain) on short-term investments Prepaid expenses Purchase of short-term investments Payment of fees for issuance of common stock ATM Fees Class A Convertible Preferred Stock Common Stock Common Stock [Member] Additional Paid-in Capital Accumulated Deficit BUSINESS GOING CONCERN SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Schedule of Anti-Dilutive Securities PREPAID EXPENSES Schedule of Prepaid Expenses Insurance Research and Development Legal Other ACCRUED EXPENSES Schedule of Accrued Expenses Research and development Accrued fees for issuance of common stock Professional fees Accrued bonus Accrued vacation Other STOCK APPRECIATION RIGHTS Schedule of Changes in SARs Schedule of Changes in Options Weighted Average Remaining Contractual Term,Outstanding Balance Weighted Average Remaining Contractual Term, Outstanding Balance Number of Option, Granted Number of Options, Granted Weighted Average Exercise Price, Granted Weighted Average Remaining Contractual Term, Granted Aggregate Intrinsic Value, Granted Weighted Average Exercise Price, Cancelled/Forfeited Aggregate Intrinsic Value, Cancelled/Forfeited Number of Option, vested Weighted Average Exercise Price, SARs vested Weighted Average Remaining Contractual Term, SARs vested Vested term Aggregate Intrinsic Value, SARs vested STOCKHOLDERS’ EQUITY Aggregate Intrinsic Value, Granted Weighted Average Exercise Price, Cancelled Aggregate Intrinsic Value, Cancelled Number of Options, Options exercisable Weighted Average Exercise Price, Options exercisable Weighted Average Remaining Contractual Term, Options exercisable Term of stock options Aggregate Intrinsic Value, Options exercisable Schedule of Weighted Average fair Value of Options Granted Risk free interest rate Dividend yield Expected dividends Volatility Expected volatility Expected term (in years) Expected life Schedule of Changes in Outstanding Warrants Number of Shares, Granted Weighted Average Exercise Price Per Share, Granted Number of Shares, Exercised Weighted Average Exercise Price Per Share, Exercised Number of Shares, Warrants exercisable Weighted Average Exercise Price Per Share Warrants exercisable Schedule of Components of Stock-Based Compensation Expense Total compensation expense Stock-based Compensation Expense COMMITMENTS AND CONTINGENCIES OTHER POSTRETIREMENT BENEFIT PLAN SEGMENT REPORTING Schedule of Operating Expenses of Our Clinical Stage Drug Development Segment Clinical Study Expense Other Research Expense Research and development compensation expense (in Dollars) Manufacturing and Drug Storage Expense Compensation Expense SUBSEQUENT EVENTS Number of Option, Cancelled/Forfeited Number of Options, Cancelled